Zorex-ER

Quick links to important sections

Zorex-ER

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Zorex-ER

Quick Facts

Property Description
Active Ingredient Divalproex Sodium
Form Extended-Release Tablet (ER)
Pharmacological Class Anticonvulsant, Mood Stabilizer
Common Use (General) Neurological Stability
Origin Synthetic Derivative

What Type of Medicine is Zorex-ER?

Zorex-ER is a prescription pharmaceutical chemically known as Divalproex Sodium, a compound clinically recognized for its effectiveness as both an Anticonvulsant (Anti-epileptic Drug) and a Mood Stabilizer. This dual-class membership signifies its capacity to regulate both abnormal electrical activity and chemical imbalances in the central nervous system. The active substance is synthesized as a Fatty acid derivative anticonvulsant, confirming its origin as an engineered compound rather than a natural one. The compound officially referred to as Divalproex Sodium is a stable combination of Sodium Valproate and Valproic Acid, designed for optimal therapeutic delivery.

Composition and Form: The Extended-Release (ER) Tablet

The medication is specifically supplied as an extended-release tablet (ER) for oral administration. This formulation is a distinguishing feature from standard valproate salts; it is engineered with a specialized coating to ensure the medicine is released gradually and consistently over a full twenty-four-hour period. This sustained-release profile is a key differentiating factor, helping to mitigate the sharp fluctuations in drug concentration that immediate-release forms may cause, which facilitates a simplified administration schedule and promotes continuous neurological stability.

What is the General Purpose of Zorex-ER?

The general purpose of Zorex-ER is to promote and sustain continuous neurological stability by enhancing inhibitory signals and stabilizing electrical activity in the brain. It chiefly achieves this by increasing the availability of the inhibitory neurotransmitter, GABA (gamma-aminobutyric acid). By stabilizing the electrical activity, the medicine provides the fundamental benefit of suppressing the excessive, repetitive firing of nerve cells that cause neurological instability, a principle that underpins its utility in balancing the central nervous system.

Regulatory References

  1. National Library of Medicine (NIH)
  2. NIH/NLM article on Mood Stabilizers
  3. NIH/NLM article on GABA

What side effects are possible with Zorex-ER?

Possible Side Effects and Safety Information

The safety profile of Zorex-ER (Divalproex Sodium) is characterized by a range of adverse reactions classified by frequency and critical warnings highlighted by regulatory authorities.

Frequency-Classified Adverse Reactions

Adverse reactions are formally categorized based on the likelihood of occurrence, as documented in official regulatory sources:

  • Very Common (affecting ge 1 in 10 patients): Nausea and Tremor.
  • Common (affecting ge 1 in 100 patients): Vomiting, Somnolence (Drowsiness), Headache, Weight gain, Alopecia (Hair loss), and Thrombocytopenia (low platelet count). Reactions affecting the gastrointestinal system often occur at the start of treatment and generally resolve within a few days.

Serious Adverse Reactions

Official safety documents highlight critical, serious adverse reactions that affect major organ systems:

  • Hepatotoxicity: Serious, sometimes fatal, liver failure that usually occurs during the first six months of treatment. This risk is significantly increased in children under the age of two years and patients with certain genetic (POLG) mutations.
  • Pancreatitis: Life-threatening inflammation of the pancreas, which has been reported both shortly after initial exposure and after several years of use.
  • Suicidal Behavior and Ideation.
  • Severe Cutaneous Adverse Reactions (SCARs): Including Stevens-Johnson Syndrome (SJS), Toxic Epidermal Necrolysis (TEN), and Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS).

Population-Specific Safety Constraints

The regulatory profile includes specific limitations for certain groups:

  • Fetal Risk: The medicine is associated with a risk of major congenital malformations (such as neural tube defects) and decreased IQ following in utero exposure. Use in women of childbearing potential is constrained due to these risks.
  • Urea Cycle Disorders (UCDs): The medicine is contraindicated in patients with known UCDs due to the risk of fatal hyperammonemic encephalopathy.
  • Older Adults: This group is more likely to experience certain unwanted effects, such as tremors or unusual somnolence.

Overdose and Emergency Response

The official regulatory profile for Zorex-ER (Divalproex Sodium) overdose centers on a documented progression of toxicity, requiring immediate medical intervention.

Overdose Manifestations

Acute overdosage is formally documented to present with Central Nervous System (CNS) depression, spanning a continuum from somnolence and lethargy to deep coma. Physiological signs include respiratory depression, hypotension, bradycardia, and miosis. Gastrointestinal distress, such as nausea and vomiting, may also occur. Life-threatening outcomes include cerebral edema, hyperammonemic encephalopathy, and high anion gap metabolic acidosis.

When to Seek Urgent Help

Immediate medical attention is required for any suspected overdose. Urgent medical evaluation must also be sought for non-specific symptoms like persistent vomiting or abdominal pain, as these may signal documented, serious complications. Management is symptomatic and supportive; procedures include gastrointestinal decontamination, and enhanced elimination measures, such as hemodialysis, are required for life-threatening toxicity associated with excessive serum concentrations. While no universal specific antidote is known, targeted interventions, such as the potential use of naloxone for CNS depression, are documented in the management of overdose. Children under two years of age are documented to have an increased risk of fatal hepatotoxicity.

Therapeutic Uses of Zorex-ER

What Zorex-ER Treats: Main Uses and Benefits

Zorex-ER (Divalproex Sodium Extended-Release) is commonly used to support neurological stability and therapeutic management across three primary domains characterized by episodic or fluctuating manifestations. It is applied in clinical settings marked by disruptive symptom manifestations that interfere with daily function. Established clinical applications encompass these core therapeutic areas.

The medication is relevant in three key contexts: managing symptoms of seizure disorders (such as complex partial and absence seizures), supporting stability in acute episodes of Bipolar Disorder, and the prophylactic management of chronic migraine headaches. The overarching benefit is to assist with maintaining functional stability and supports the patient during difficult episodes.

Managing Symptoms of Seizure Disorders and Epilepsy

This medication is commonly used to manage various seizure disorders, which present with symptoms like uncontrolled movements or temporary loss of awareness. The use is relevant for easing symptoms related to neurological discharges, providing support that helps ease the overall symptom burden.

“The primary goal of this therapeutic approach is to help patients cope more steadily with symptom fluctuations and supports general well-being during symptomatic phases.”

Supporting Stability in Acute Episodes of Bipolar Disorder

Zorex-ER is relevant in conditions characterized by periods of heightened symptoms, specifically to address the acute symptomatic episodes of Bipolar Disorder. It is applied to help manage distressing manifestations such as abnormally elevated, irritable, or expansive moods. This offers a supportive therapeutic benefit that contributes to improving emotional stability and helps improve day-to-day comfort during symptomatic periods.

Prophylactic Management of Chronic Migraine Headaches

This compound is utilized in clinical scenarios for the preventive management of frequent, recurrent migraine headaches. The use is relevant for easing symptoms related to their painful intensity and may assist with reducing the frequency of attacks, which supports general well-being during symptomatic phases.

Quick Fact: Relief for Key Symptom Patterns
Epilepsy Supports the management of symptoms related to uncontrolled neurological discharges.
Bipolar Contributes to improving emotional stability during acute manic or mixed episodes.
Migraine May assist in reducing the frequency and intensity of recurrent attacks.

Regulatory References

  1. U.S. National Library of Medicine DailyMed information on Divalproex Sodium

Eligibility and Restrictions for Use

Official Eligibility and Non-Eligibility for Zorex-ER

Zorex-ER (Divalproex Sodium) is governed by strict population-eligibility rules established by government regulatory bodies.

Absolute Contraindications (Must Not Use)

Regulatory agencies prohibit the use of Zorex-ER in patients with:

  • Hepatic Disease or Significant Hepatic Dysfunction.
  • Known Urea Cycle Disorders (UCD).
  • Known Mitochondrial Disorders caused by mutations in mitochondrial DNA polymerase gamma (POLG).
  • Known Hypersensitivity (allergy) to Divalproex Sodium or related compounds.

Pregnancy and Childbearing Potential

  • Migraine Prophylaxis: Use is absolutely contraindicated in pregnant women and women of childbearing potential not using effective contraception.
  • Epilepsy/Bipolar Disorder: Use in pregnant women is not recommended unless other treatments have failed or are unacceptable.
  • Lactation: The drug passes into breast milk. Use requires careful weighing of potential benefits against potential risks, as infant safety data are limited.

Age-Related and Conditional Use

Population Eligibility Status Restriction/Limitation
Children under 2 years Extreme Caution Higher risk of fatal hepatotoxicity. Contraindicated if a POLG-related disorder is suspected.
Children under 10 years Limited Use Safety and efficacy not established for all approved uses.
Older Adults (Geriatric) Conditional Use Starting doses must be reduced, and dose escalation must be slowed due to risk of adverse effects.

These limitations ensure the medicine is used only when the regulatory safety profile is deemed acceptable for the defined population.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Zorex-ER (Divalproex Sodium) interaction patterns are defined by its capacity to modify the metabolism of other medications and its potential for additive pharmacodynamic effects, as described in official government labeling.

Contraindicated Combinations

Co-administration with Carbapenem antibiotics (e.g., Meropenem, Ertapenem) is formally contraindicated. This combination carries a significant risk of rapidly and profoundly reducing Valproate plasma concentrations, potentially resulting in loss of neurological control.

Pharmacokinetic and Exposure Alterations

The medicine is subject to metabolic interactions. Hepatic enzyme-inducing drugs (e.g., Phenytoin, Carbamazepine, Rifampin) can increase Valproate clearance, potentially reducing its concentration. Conversely, Divalproex Sodium can inhibit the clearance of co-administered drugs like Lamotrigine and Phenobarbital, significantly increasing their exposure and risk of toxicity. Concomitant use with Aspirin may also increase Valproate plasma levels due to reduced clearance.

Specific Interaction Risks

  • Combining Zorex-ER with Topiramate is associated with a specific regulatory caution due to an increased risk of hyperammonemia and encephalopathy.
  • Co-ingestion of Alcohol is not recommended during treatment due to the documented potential for enhanced sedation and risk of liver damage.
  • Valproate may potentiate the effects of other CNS depressants (e.g., antipsychotics, benzodiazepines), which requires careful consideration.

Mechanism of Action

How Zorex-ER Works

The action of Zorex-ER (Divalproex Sodium) is defined by a multi-modal pharmacological mechanism that reduces the physiological intensity of electrical and chemical signal transmission in the central nervous system. The active component, the valproate ion, simultaneously engages three primary domains that influence key regulatory processes within the central nervous system.


Modulation of CNS Inhibitory Signaling

This domain targets the chemical environment of nerve cells by enhancing the CNS's principal inhibitory pathway, the GABAergic system. The drug achieves this primarily by inhibiting GABA Transaminase (GABA-T), the enzyme responsible for breaking down the inhibitory neurotransmitter GABA, leading to elevated levels of GABA at the synaptic level. This increased GABA activity raises the overall inhibitory tone of the CNS, which reduces the level of network excitability.


Regulation of Neuronal Electrical Conduction

This mechanism directly addresses the electrical properties of nerve cells. The valproate ion acts as a blocker of key voltage-gated ion channels, specifically stabilizing Sodium Channels and inhibiting T-type Calcium Channels. By limiting the capacity of these channels to propagate current, the drug directly reduces the ability of nerve cells to initiate and sustain rapid, repetitive firing.


Influence on Long-Term Cellular Processes

A third mechanism involves the inhibition of Histone Deacetylases (HDACs), a nuclear enzyme system. This action subtly alters the gene expression within the nerve cell (epigenetic modulation), influencing long-term neuronal function and regulatory processes.

Dosage and Administration Information

Zorex-ER (Divalproex Sodium Extended-Release) is intended for standardized application. The official instructions define the required route of administration, daily frequency, dose titration schedules, and specific tablet handling rules.

Official Administration Guidelines

The medication is delivered via oral administration and is scheduled for once-daily intake. The extended-release tablet must be swallowed whole and must not be crushed or chewed, as this would compromise the specialized formulation's sustained-release properties.

Indication-Specific Starting Doses
Acute Mania: Initial dose of 25 mg/kg/day. Dose is increased as rapidly as possible to achieve therapeutic response.
Seizures: Initial dose of 10 to 15 mg/kg/day. Dose is increased at 1-week intervals by 5 to 10 mg/kg/day until optimal clinical response.
Migraine Prophylaxis: Initial dose of 500 mg/day for 1 week, followed by a maintenance dose of 1000 mg/day.

Procedural and Population-Specific Rules

The maximum recommended dosage for seizures and acute mania is 60 mg/kg/day. The drug is approved for use in patients 10 years of age and older for seizure conditions. When switching a patient from the immediate-release formulation, the total daily dose of the extended-release tablet should be 8% to 20% higher than the immediate-release total daily dose. For older adults, guidelines advise using a reduced starting dose and a slower rate of dosage increase.

Recent Clinical Evidence

Research evidence / Overview of studies for Zorex-ER


Evidence for use in Acute Manic/Mixed Episodes

Research for this use was studied for conditions characterized by acute or disruptive episodes of Bipolar Disorder. Studies primarily consisted of short-term Randomized Controlled Trials (RCTs). These studies were conducted during periods of increased symptom activity, typically lasting about three weeks, comparing the compound to an inactive substance (placebo). Researchers examined outcomes related to episodic or acute changes using standardized clinical scales, such as the Young Mania Rating Scale (YMRS), to measure symptom patterns in adults and some pediatric patients. The findings describe patterns observed where measurements of symptom changes were recorded in the active drug group. What remains uncertain is the long-term characterization for sustained stability, as long-term effects are not fully established by controlled trials for this extended-release formulation.


Evidence for use in Seizure Disorders (Epilepsy)

The evidence base for Zorex-ER in seizure disorders was evaluated in numerous trials, including monotherapy (single-drug) and adjunctive therapy studies. Research examined outcomes related to systemic or functional imbalance, such as the rate of seizures, in populations of adults and children (typically aged 10 and older). Studies monitored the number of neurological events and the proportion of patients achieving a specific change in frequency. Studies explored how seizure count measurements evolved in the observed populations during the study period. Research describes data related to the active compound's application across a broad spectrum of seizure types. However, comparative evidence is lacking for long-term outcomes between the ER formulation and the original immediate-release form in all patient groups.


Evidence for the Prophylaxis of Chronic Migraine Headaches

This use was studied for conditions characterized by fluctuating or episodic manifestations in adults. Research primarily used Randomized Controlled Trials (RCTs) over medium-term intervals (12 to 16 weeks), comparing the drug to a placebo. Studies explored outcomes related to physical discomfort, specifically measuring the 4-week migraine headache rate. Research highlights the patterns measured during the study period, which showed differences in the average rate of attacks between the active drug group and the placebo group in adults. Research findings were mixed when examining specific subgroups, particularly in adolescent populations. Results apply only to the populations studied and do not provide insight into acute pain relief.

Key Studies & References Divalproex Sodium Extended-Release Tablets - Official Label Information and Clinical Trial Summary (All Approved Indications)

Frequently Asked Questions (FAQ)

Common questions about Zorex-ER (FAQ)

Q: Why is Zorex-ER available only with a prescription?

A: Due to the potential for serious and sometimes life-threatening side effects, Zorex-ER is classified as a prescription-only medicine. The requirement for a prescription emphasizes the necessity of professional oversight due to the complex risk profile. This allows a healthcare provider to guide the decision-making process based on the documented risks and benefits.

Q: Does Zorex-ER carry a 'Black Box Warning' in the US?

A: Yes, Zorex-ER carries a Boxed Warning (often called a Black Box Warning) in the United States. This is the strictest warning required by the FDA and highlights the serious potential risks of liver damage, life-threatening inflammation of the pancreas (pancreatitis), and significant risk of fetal harm if used during pregnancy.

Q: How is Zorex-ER chemically different from standard Zorex tablets?

A: According to the official product information, Zorex-ER contains the same active compound, divalproex sodium, as the standard formulations. The key difference is the extended-release design. This specialized engineering allows the medicine to be delivered slowly and consistently over a 24-hour period, facilitating a simplified, once-daily intake schedule.

Q: What technology is used to create the extended-release formulation of Zorex-ER?

A: The extended-release formulation is designed with a specific coating technology. This coating is engineered to control the rate at which the active medicine is released into the body. This sustained release profile is essential for maintaining steady levels of the medication over a full 24-hour cycle.

Q: Is Zorex-ER intended to be taken at the same time every day?

A: Official patient guides indicate that taking the medicine at the same time every day is important to achieve the best potential therapeutic outcome. This consistency is crucial because it helps maintain a stable, continuous concentration of the medicine in the blood, which supports neurological stability.

Q: Does Zorex-ER need to be taken at a specific time relative to meals?

A: According to the official patient administration instructions, Zorex-ER can be taken either with food or on an empty stomach. Official administration instructions note that taking the medicine with food may help reduce common gastrointestinal issues like stomach upset.

Q: What general action should be taken regarding a dose of Zorex-ER that has been missed?

A: General patient instructions describe that if an individual misses a dose, it can be taken as soon as it is remembered. If it is nearly time for the next scheduled dose, the individual should omit the missed dose entirely. Official guidance states that taking two doses to compensate should be avoided.

Q: What kind of changes can be expected if Zorex-ER is stopped abruptly?

A: Official safety documents strongly advise against suddenly stopping Zorex-ER treatment. Abrupt cessation can lead to severe consequences, including the possibility of triggering acute withdrawal seizures or causing the underlying condition's symptoms to rapidly return.

Q: Are there any reported long-term side effects associated with Zorex-ER?

A: Regulatory documents highlight that some serious risks, such as life-threatening pancreatitis or suicidal thoughts, can occur at any time—either when first starting treatment or after several years of use. In general, long-term use is associated with a risk of cognitive impairment and liver damage.

Q: Do the common side effects of Zorex-ER typically go away over time?

A: Official product information indicates that many of the most common side effects, particularly nausea and other gastrointestinal issues, often diminish or completely resolve over time. This improvement generally occurs within the first few days or weeks after starting treatment.

Q: Can Zorex-ER cause mood changes or depression?

A: Official regulatory information indicates that Zorex-ER may cause various mood changes. These can include new or worsened depression, feelings of anxiety, irritability, and in a small number of people, suicidal thoughts or actions.

Q: Could Zorex-ER affect a person's ability to drive or operate machinery?

A: Yes, common side effects such as drowsiness, sedation, and confusion can impair concentration and coordination. Official patient warnings indicate that caution is advised when engaging in activities like driving or operating complex machinery. This caution applies until an individual is aware of how the medication affects their personal state.

Q: Does Zorex-ER interact with common herbal supplements like St. John's Wort?

A: Yes, official interaction reviews indicate that Zorex-ER may interact with the herbal supplement St. John’s Wort. This combination could potentially increase the likelihood of neurological side effects, such as heightened dizziness, drowsiness, confusion, and concentration difficulty.

Q: Is there a specific drug interaction warning between Zorex-ER and grapefruit?

A: There is no formal contraindication for grapefruit juice listed in official prescribing information. However, clinical understanding indicates that grapefruit may affect certain liver enzymes that process medicines like Zorex-ER. This raises the possibility of causing fluctuations in the concentration of medicine in the body.

Q: Are there any known dietary restrictions other than alcohol or grapefruit to observe with Zorex-ER?

A: While official documents caution against alcohol and certain interactions, there are no specific dietary restrictions for common foods. Official guidance suggests that consistency in the method of intake—either consistently with food or consistently without food—is important to help stabilize the drug's levels.

Q: How is the Zorex-ER compound typically processed and eliminated by the body?

A: The medicine is processed almost entirely by the body’s detoxification system, which is centered in the liver (hepatic system). The active compound is broken down primarily through a chemical process called conjugation. Only a very small amount of the administered dose is eliminated unchanged via the kidneys and urine.

Q: What is the eligibility of Zorex-ER use for patients who have impaired kidney function?

A: Since Zorex-ER is processed mainly by the liver, official documents state that a standard dose change is not typically required solely for impaired kidney function. However, kidney issues can affect how the medicine binds to proteins in the blood, which means special monitoring of the drug's levels may be necessary.

Q: What kind of medical monitoring is usually required when taking Zorex-ER?

A: Regulatory guidance requires that Liver Function Tests (LFTs) are performed before starting therapy. This monitoring must be repeated at frequent intervals, especially during the first six months of treatment.

Q: Can Zorex-ER affect laboratory test results?

A: Yes, Zorex-ER may affect the results of certain laboratory tests. For example, it is known to affect liver function test results and can also interfere with the accuracy of blood-level monitoring, especially in individuals with impaired kidney function.

Q: What should be done if an allergic reaction to Zorex-ER is suspected?

A: If an individual suspects signs of an allergic reaction, they should contact a healthcare provider promptly. For severe symptoms, particularly trouble breathing or swelling of the face, official guidelines indicate that seeking immediate emergency medical attention is necessary.

Q: Does Zorex-ER have a known risk of dependence or withdrawal symptoms?

A: Regulatory information emphasizes that discontinuation of the medicine should be done gradually and only under the direction of a healthcare professional. Abrupt cessation can lead to severe clinical consequences, including the potential for withdrawal seizures.

Q: What is the official, approved maximum length of time for Zorex-ER treatment?

A: For chronic conditions like epilepsy or bipolar disorder, Zorex-ER is generally intended for long-term treatment. Once the condition is stable, official patient information suggests that continuous therapy may be necessary and may last for many years to maintain control of symptoms.

Q: Is Zorex-ER intended for short-term or long-term therapeutic use?

A: Zorex-ER is generally intended for long-term therapeutic use to help maintain continuous neurological stability. While the initial clinical trials were short-term, the therapeutic goal for its approved indications requires ongoing treatment.

Q: Does Zorex-ER have a reported effect on blood pressure or heart rate?

A: Routine use of Zorex-ER does not commonly report effects on blood pressure or heart rate. However, official safety documentation warns that taking an excessive amount of the medicine (overdose) can lead to dangerous and irregular changes in heart rate and rhythm.

How should Zorex-ER be stored and disposed of?

How to Store and Dispose of Zorex-ER?

Zorex-ER (Divalproex Sodium Extended-Release Tablets) requires specific conditions to maintain its stability and integrity, as defined by official regulatory labeling.

Required Storage Conditions

Detail Requirement
Temperature Store at Controlled Room Temperature between 20 C to 25 C.
Protection Must be protected from light and moisture.
Container Keep the container tightly closed.
Handling Tablets must be swallowed whole; do not crush or chew.

Safety and Disposal

For safety, the medication must be stored out of the sight and reach of children and pets. Unused or expired Zorex-ER should be properly discarded. The official instruction is to not flush the tablets down the toilet or pour them into a drain; instead, consult a pharmacist or local waste disposal company for safe methods.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Zorex-ER found in:

A-Z Index: